- Home
- PRPL vs HLVX Comparison
PRPL vs HLVX Comparison
Compare PRPL & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- HLVX
- Stock Information
- Founded
- PRPL 2010
- HLVX 2020
- Country
- PRPL United States
- HLVX United States
- Employees
- PRPL N/A
- HLVX N/A
- Industry
- PRPL Home Furnishings
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- HLVX Health Care
- Exchange
- PRPL Nasdaq
- HLVX Nasdaq
- Market Cap
- PRPL 99.7M
- HLVX 87.6M
- IPO Year
- PRPL N/A
- HLVX 2022
- Fundamental
- Price
- PRPL $0.85
- HLVX $1.80
- Analyst Decision
- PRPL Buy
- HLVX Hold
- Analyst Count
- PRPL 4
- HLVX 5
- Target Price
- PRPL $2.53
- HLVX $2.33
- AVG Volume (30 Days)
- PRPL 370.9K
- HLVX 130.3K
- Earning Date
- PRPL 11-04-2024
- HLVX 11-07-2024
- Dividend Yield
- PRPL N/A
- HLVX N/A
- EPS Growth
- PRPL N/A
- HLVX N/A
- EPS
- PRPL N/A
- HLVX N/A
- Revenue
- PRPL $504,838,000.00
- HLVX N/A
- Revenue This Year
- PRPL N/A
- HLVX N/A
- Revenue Next Year
- PRPL $2.63
- HLVX N/A
- P/E Ratio
- PRPL N/A
- HLVX N/A
- Revenue Growth
- PRPL N/A
- HLVX N/A
- 52 Week Low
- PRPL $0.59
- HLVX $1.55
- 52 Week High
- PRPL $2.33
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- PRPL 42.62
- HLVX 41.10
- Support Level
- PRPL $0.79
- HLVX $1.80
- Resistance Level
- PRPL $0.89
- HLVX $2.02
- Average True Range (ATR)
- PRPL 0.05
- HLVX 0.07
- MACD
- PRPL 0.00
- HLVX -0.02
- Stochastic Oscillator
- PRPL 25.64
- HLVX 0.00
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms, and other products. It sells its products through online channels, traditional wholesale partners and third-party online retailers.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.